{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Powder&page=21",
    "query": {
      "intervention": "Study Powder",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 1207,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Powder&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Powder&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T04:33:30.936Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02924688",
      "title": "A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FF/UMEC/VI (100/31.25/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI (100/62.5/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI (200/31.25/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI (200/62.5/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/VI (100/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/VI (200/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone/salmeterol (FSC)",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/salbutamol",
          "type": "DRUG"
        },
        {
          "name": "ELLIPTA DPI",
          "type": "DEVICE"
        },
        {
          "name": "DISKUS DPI",
          "type": "DEVICE"
        },
        {
          "name": "METERED-DOSE INHALER (MDI)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2436,
      "start_date": "2016-10-13",
      "completion_date": "2019-02-22",
      "has_results": true,
      "last_update_posted_date": "2021-03-26",
      "last_synced_at": "2026-10-31T04:33:30.936Z",
      "location_count": 99,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02924688"
    },
    {
      "nct_id": "NCT04090203",
      "title": "Boiled Peanut Oral Immunotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peanut Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "Boiled Peanut Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alton Melton",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "1 Year to 16 Years"
      },
      "enrollment_count": 8,
      "start_date": "2019-11-05",
      "completion_date": "2021-05-20",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-31T04:33:30.936Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04090203"
    },
    {
      "nct_id": "NCT03298867",
      "title": "Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease",
        "Graves' Orbitopathy"
      ],
      "interventions": [
        {
          "name": "Teprotumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 83,
      "start_date": "2017-10-04",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-10-31T04:33:30.936Z",
      "location_count": 9,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03298867"
    },
    {
      "nct_id": "NCT03992404",
      "title": "Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "NT 201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz Pharmaceuticals GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 603,
      "start_date": "2019-09-16",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-31T04:33:30.936Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Brandenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03992404"
    },
    {
      "nct_id": "NCT06609161",
      "title": "A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tedizolid Phosphate Oral Formulation 1 (Reference)",
          "type": "DRUG"
        },
        {
          "name": "Tedizolid Phosphate Oral Formulation 2 (Test)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2024-07-16",
      "completion_date": "2024-08-08",
      "has_results": false,
      "last_update_posted_date": "2024-09-27",
      "last_synced_at": "2026-10-31T04:33:30.936Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06609161"
    },
    {
      "nct_id": "NCT07226362",
      "title": "A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety, and Tolerability"
      ],
      "interventions": [
        {
          "name": "DHE inhalation powder low dose administered via dry powder inhaler (DPI) device",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "DHE inhalation powder high dose administered via dry powder inhaler (DPI) device",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "DHE injected intravenously (1 mg)",
          "type": "DRUG"
        },
        {
          "name": "DHE 2 mg administered by nasal spray (Migranal®)",
          "type": "DRUG"
        },
        {
          "name": "Metoclopramide 10mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Aspeya Switzerland SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2025-06-09",
      "completion_date": "2025-10-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-31T04:33:30.936Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07226362"
    },
    {
      "nct_id": "NCT01862939",
      "title": "A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "DS-7309",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 52,
      "start_date": "2011-04",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-10-31T04:33:30.936Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01862939"
    },
    {
      "nct_id": "NCT01697345",
      "title": "Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Vaginal Dryness",
        "Dyspareunia",
        "Sexual Health Quality of Life"
      ],
      "interventions": [
        {
          "name": "Testosterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Creighton University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2013-02",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-01-24",
      "last_synced_at": "2026-10-31T04:33:30.936Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01697345"
    },
    {
      "nct_id": "NCT07097259",
      "title": "A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Test: Follitropin alfa",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Reference: Follitropin alfa",
          "type": "DRUG"
        },
        {
          "name": "Zoladex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 55,
      "start_date": "2025-07-21",
      "completion_date": "2025-12-23",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-10-31T04:33:30.936Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07097259"
    },
    {
      "nct_id": "NCT03580356",
      "title": "A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "Ligelizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1078,
      "start_date": "2018-10-20",
      "completion_date": "2022-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-10-31T04:33:30.936Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03580356"
    }
  ]
}